announces that the U.S. Food and Drug Administration has accepted the Biologics License Application or BLA for its breakthrough investigational kidney cancer PET1 imaging agent TLX250-CDx ...

for its breakthrough investigational kidney cancer PET1 imaging agent TLX250-CDx (Zircaix®2, 89Zr-DFO-girentuximab), granted a Priority Review and provided a PDUFA3 date of 27 August 2025 ...

The Many Lives Of PET #1, by Stan’s Cafe and commissioned by plastics experts at the University of Birmingham, will explore our relationship to plastics.

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food ...

No description, website, or topics provided.